What are the differences between carbapenem antibiotics and penem antibiotics?

Carbapenem vs. Penem Antibiotics: Key Differences

Carbapenems and penems are closely related β-lactam antibiotics that share similar structural features and broad-spectrum activity, but penems represent a distinct subclass with specific structural modifications that differentiate them from traditional carbapenems 1, 2.

Structural and Chemical Distinctions

The fundamental difference lies in their molecular architecture. Both classes contain a β-lactam ring fused to a five-membered ring, but penems have a sulfur atom at position 1 of the five-membered ring (similar to penicillins), while carbapenems have a carbon atom at this position 2, 3. This structural variation affects their stability, spectrum of activity, and pharmacokinetic properties.

Penems share properties of penicillins, cephalosporins, and carbapenems in their chemical structure, creating a unique hybrid class 4. The carbapenem structure provides extraordinary stability against β-lactamase enzymes, while penems achieve similar but not identical resistance profiles 5, 3.

Clinical Classification

Carbapenems are divided into two groups based on their spectrum 6:

• Group 1 carbapenems: Ertapenem - active against ESBL-producing pathogens but NOT active against P. aeruginosa or Enterococcus species
• Group 2 carbapenems: Imipenem/cilastatin, meropenem, doripenem - active against non-fermentative gram-negative bacilli including P. aeruginosa

Penems currently include: Faropenem and sulopenem (with recent FDA approval for sulopenem) 1, 2, 4.

Route of Administration: A Critical Practical Difference

The most clinically significant difference is that penems can be administered orally, while most carbapenems require parenteral administration 1. This represents a major therapeutic advantage:

• Oral penems: Faropenem and sulopenem (as sulopenem etzadroxil prodrug) are available for oral use
• Oral carbapenem: Only tebipenem has oral formulation
• Parenteral carbapenems: Imipenem, meropenem, doripenem, ertapenem require IV administration

The oral bioavailability of sulopenem is 20-34% under fasted conditions but significantly improves (62% increase in AUC) when administered with food and probenecid 4.

Spectrum of Activity Differences

While both classes have broad-spectrum coverage, penems demonstrate some distinct activity patterns 4:

Penem advantages:

• Greater activity than meropenem and ertapenem against Enterococcus faecalis, Listeria monocytogenes, MSSA, and S. epidermidis
• Nearly identical activity to ertapenem and meropenem against ESBL-producing E. coli and K. pneumoniae
• Greater activity than imipenem against many anaerobes including Bacteroides fragilis

Penem limitations:

• Generally less activity against gram-negative aerobes compared to ertapenem and meropenem (with some exceptions)
• No activity against P. aeruginosa or P. mirabilis (for sulopenem specifically)
• Inactive against MRSA, carbapenemase-producing Enterobacterales, and Stenotrophomonas maltophilia

Pharmacokinetic Considerations

Carbapenems (imipenem, meropenem, doripenem) have 7:

• Volumes of distribution: 15.8-27.6 L
• Elimination half-lives: 0.88-1.03 hours
• Post-antibiotic effect against P. aeruginosa (unique among β-lactams)
• Time-dependent killing requiring frequent dosing

Penems (sulopenem) demonstrate 4:

• Similar pharmacokinetics to carbapenems when given IV
• Variable urine concentrations (21.8-609.0 mg/L)
• Approximately 10% protein binding
• 35.5% recovered unchanged in urine

Clinical Applications

Carbapenems should be reserved for 8:

• Hospital-acquired severe infections with ≥2 risk factors (prior broad-spectrum antibiotic use, ESBL carriage, recent hospitalization)
• Severe sepsis/septic shock with known ESBL colonization
• NOT for routine community-acquired infections

Penems (specifically sulopenem) are indicated for 1, 4:

• Uncomplicated and complicated urinary tract infections
• Fluoroquinolone-resistant, ESBL-producing, MDR Enterobacterales UTIs
• Oral stepdown therapy after IV carbapenem treatment
• Patients requiring outpatient therapy for resistant pathogens

Resistance Mechanisms

Both classes face similar resistance challenges 3, 4:

• Carbapenemase production (KPC, NDM, VIM, OXA-48-like)
• Altered penicillin-binding proteins
• Reduced outer membrane protein expression
• Efflux pump overexpression

A critical stewardship consideration: Carbapenem use should be limited to preserve activity due to emerging carbapenem resistance 6. Penems may offer carbapenem-sparing options for specific indications, particularly UTIs.

Common Pitfalls

• Do not assume all carbapenems cover P. aeruginosa - ertapenem does NOT
• Do not use penems for Pseudomonas infections - they lack this coverage
• Do not administer oral penems without food and probenecid - bioavailability is significantly compromised
• Do not use either class empirically for community-acquired infections without specific risk factors for resistant organisms